Tiba announces a BARDA FASTx award to develop an RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein using Tiba’s novel RNABL™ delivery platform
The government of NSW (Australia) is investing in a range of animal disease vaccines with leading institutions and technology providers, including Tiba Biotech. A pilot project intended to fast-track an mRNA vaccine for border disease virus (BDV) has been successfully manufactured for the first time in NSW.
NIH awards Tiba a Phase II SBIR grant to advance RNA vaccines against pandemic influenza
September 5, 2023
Tiba Biotech receives an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
CEPI Partners with Tiba Biotech to Evaluate Next-Generation RNA Vaccine Platform Technology to Respond to ‘Disease X’
January 12, 2023
As the first award to be granted under CEPI’s innovation program, CEPI will provide US$2 million to advance Tiba Biotech’s novel RNA nanoparticle delivery platform, RNABL™.
Tiba Biotech announces the extension of an earlier CIVICs initiative with scientists from the University of Minnesota and Emory University to study the level and duration of protection of Tiba’s next-generation RNA vaccines.
Tiba Biotech and the Australian State of New South Wales Enter Partnership to Address Emergency Animal Disease Threats
September 27, 2022
Tiba Biotech, a preclinical biopharmaceutical company, today announced it has entered into a five-year, multi-million US dollar agreement with the Australian state government of New South Wales (NSW) to develop next-generation mRNA vaccines against emergency animal diseases that threaten Australia’s livestock industry and domestic food security.
Tiba Biotech announces a new collaboration with leading researchers at the Cummings School of Veterinary Medicine of Tufts University to develop next generation vaccines against emerging tick-borne diseases (TBDs).
Tiba Biotech receives a Notice of Intent from NIAID to fund a Phase I SBIR to develop a novel RNA vaccine against a deadly tick bourn disease with the Cummings School for Veterinary Medicine
Tiba Biotech receives a Phase I SBIR grant from NIAID to develop a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
© 2024 Tiba Biotech LLC. All rights reserved
Keep connected with us
Terms and Conditions
